Did Achieve Life beat or miss consensus estimates last quarter?

What is Achieve Life's gross profit margin?

What is Achieve Life's latest dividend and current dividend yield?

What is the market's earnings forecast for Achieve Life next quarter?

What is the revenue and EPS growth rate for Achieve Life year over year?

What were the key takeaways from Achieve Life's earnings call?

What guidance did Achieve Life's management provide for the next earnings period?

What were the key takeaways from Achieve Life’s earnings call?

- **FDA Milestones**: Smoking cessation NDA set for June 2026 approval; vaping indication could launch 8 months earlier with CNPV.
- **Clinical Success**: COPD smokers achieved comparable quit rates to non-COPD patients, with 97% patient satisfaction.
- **Commercial Readiness**: AI-driven platform and dual distribution strategy (specialty + retail) to maximize reach.
- **Financial Health**: $48.1M cash runway into 2026, but additional funding needed for vaping trial.
- **Market Differentiation**: 5x lower nausea/vomiting incidence vs. CHANTIX, targeting 7M highly motivated smokers and 17M vapors.

**【CEO Summary Section】**
- **CNPV for Vaping**: Received FDA's Commissioner's National Priority Voucher, reducing NDA approval timeline to 1-2 months for vaping cessation, potentially launching 8 months earlier than smoking cessation.
- **Smoking Cessation Milestones**: FDA accepted NDA with PDUFA date set for June 20, 2026. Submitted 120-day safety update, showing no serious adverse events in 411 participants.
- **Clinical Efficacy**: COPD smokers achieved quit rates comparable to non-COPD patients (5.3 vs. 5.2 odds ratio), with 97% of participants believing cytisinicline helped reduce nicotine use.
- **Commercial Strategy**: AI-driven platform for targeted marketing, specialty and retail distribution, and payer engagement to ensure access.
- **Team Expansion**: Promoted Dr. Mark Rubenstein to CMO, Craig Donnelly to COO, and hired Eric Atkinson as CLO.

**【CFO Financial Commentary】**
- **Cash Position**: $48.1 million as of Q3 2025, runway into H2 2026 without additional funding for smoking cessation launch.
- **Operating Expenses**: $14.7 million for Q3, $40.1 million YTD, reflecting investments in regulatory and commercial activities.
- **Net Loss**: $14.4 million for Q3, $40 million YTD.
- **Funding Needs**: Additional capital required for vaping Phase III trial, with no current plans to use existing cash runway.

**【Q&A Highlights】**
- **Distribution Strategy**: Initial focus on specialty pharmacies, complemented by retail channels post-launch.
- **Vaping Study Protocol**: Similar to smoking trials (12-week, 400-patient arms), with blood/saliva biomarkers for nicotine confirmation.
- **Pfizer's CHANTIX**: Cytisinicline's superior safety profile (5x less nausea/vomiting) positions it as a differentiated competitor.
- **Dual Launch Risks**: Separate targeting for smokers (older, digitally inclined) and vapors (younger, digitally native), with shared physician engagement strategy.
- **Manufacturing Readiness**: Same 3mg thrice-daily dosing for both indications, with smoking cessation launch in Q3/Q4 2026.


ACHV

ACHV fundamentals

You can ask Aime